Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Benign Prostatic Hyperplasia (BPH) Treatment Revenue 1.4 Market Analysis by Type 1.4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Drugs 1.4.3 Devices 1.5 Market by Application 1.5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application: 2020 VS 2026 1.5.2 Hospitals 1.5.3 Clinics 1.5.4 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Perspective (2015-2026) 2.2 Benign Prostatic Hyperplasia (BPH) Treatment Growth Trends by Regions 2.2.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Benign Prostatic Hyperplasia (BPH) Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Market Size 3.1.1 Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Revenue (2015-2020) 3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio 3.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Treatment Revenue in 2019 3.3 Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Area Served 3.4 Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product Solution and Service 3.5 Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Historic Market Size by Type (2015-2020) 4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Type (2021-2026) 5 Benign Prostatic Hyperplasia (BPH) Treatment Breakdown Data by Application (2015-2026) 5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) 5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2015-2020) 6.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in North America (2019-2020) 6.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) 6.4 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) 7 Europe 7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2015-2020) 7.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in Europe (2019-2020) 7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) 7.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) 8 China 8.1 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2015-2020) 8.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in China (2019-2020) 8.3 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) 8.4 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) 9 Japan 9.1 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2015-2020) 9.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in Japan (2019-2020) 9.3 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) 9.4 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2015-2020) 10.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) 10.4 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) 11 India 11.1 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2015-2020) 11.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in India (2019-2020) 11.3 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) 11.4 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2015-2020) 12.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in Central & South America (2019-2020) 12.3 Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) 12.4 Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) 13Key Players Profiles 13.1 Pfizer 13.1.1 Pfizer Company Details 13.1.2 Pfizer Business Overview and Its Total Revenue 13.1.3 Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.1.4 Pfizer Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020)) 13.1.5 Pfizer Recent Development 13.2 Sanofi 13.2.1 Sanofi Company Details 13.2.2 Sanofi Business Overview and Its Total Revenue 13.2.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.2.4 Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.2.5 Sanofi Recent Development 13.3 GlaxoSmithKline 13.3.1 GlaxoSmithKline Company Details 13.3.2 GlaxoSmithKline Business Overview and Its Total Revenue 13.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.3.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.3.5 GlaxoSmithKline Recent Development 13.4 Boston Scientific 13.4.1 Boston Scientific Company Details 13.4.2 Boston Scientific Business Overview and Its Total Revenue 13.4.3 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.4.4 Boston Scientific Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.4.5 Boston Scientific Recent Development 13.5 Teleflex 13.5.1 Teleflex Company Details 13.5.2 Teleflex Business Overview and Its Total Revenue 13.5.3 Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.5.4 Teleflex Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.5.5 Teleflex Recent Development 13.6 Cardinal Health 13.6.1 Cardinal Health Company Details 13.6.2 Cardinal Health Business Overview and Its Total Revenue 13.6.3 Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.6.4 Cardinal Health Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.6.5 Cardinal Health Recent Development 13.7 Allergan 13.7.1 Allergan Company Details 13.7.2 Allergan Business Overview and Its Total Revenue 13.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.7.4 Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.7.5 Allergan Recent Development 13.8 Teva Pharmaceutical 13.8.1 Teva Pharmaceutical Company Details 13.8.2 Teva Pharmaceutical Business Overview and Its Total Revenue 13.8.3 Teva Pharmaceutical Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.8.4 Teva Pharmaceutical Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.8.5 Teva Pharmaceutical Recent Development 13.9 Mylan 13.9.1 Mylan Company Details 13.9.2 Mylan Business Overview and Its Total Revenue 13.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.9.4 Mylan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.9.5 Mylan Recent Development 13.10 Eli Lilly 13.10.1 Eli Lilly Company Details 13.10.2 Eli Lilly Business Overview and Its Total Revenue 13.10.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Introduction 13.10.4 Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) 13.10.5 Eli Lilly Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Benign Prostatic Hyperplasia (BPH) Treatment Key Market Segments Table 2. Key Players Covered: Ranking by Benign Prostatic Hyperplasia (BPH) Treatment Revenue Table 3. Ranking of Global Top Benign Prostatic Hyperplasia (BPH) Treatment Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Drugs Table 6. Key Players of Devices Table 7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 8. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions (US$ Million): 2020 VS 2026 Table 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions (2015-2020) (US$ Million) Table 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions (2015-2020) Table 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions (2021-2026) Table 13. Market Top Trends Table 14. Key Drivers: Impact Analysis Table 15. Key Challenges Table 16. Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Strategy Table 17. Main Points Interviewed from Key Benign Prostatic Hyperplasia (BPH) Treatment Players Table 18. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Players (2015-2020) (Million US$) Table 19. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Players (2015-2020) Table 20. Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2019) Table 21. Global Benign Prostatic Hyperplasia (BPH) Treatment by Players Market Concentration Ratio (CR5 and HHI) Table 22. Key Players Headquarters and Area Served Table 23. Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product Solution and Service Table 24. Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) (Million US$) Table 27. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Share by Type (2015-2020) Table 28. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Share by Application (2015-2020) Table 30. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) (Million US$) Table 31. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Share by Application (2021-2026) Table 32. North America Key Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue (2019-2020) (Million US$) Table 33. North America Key Players Benign Prostatic Hyperplasia (BPH) Treatment Market Share (2019-2020) Table 34. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) (Million US$) Table 35. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2015-2020) Table 36. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) (Million US$) Table 37. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2015-2020) Table 38. Europe Key Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue (2019-2020) (Million US$) Table 39. Europe Key Players Benign Prostatic Hyperplasia (BPH) Treatment Market Share (2019-2020) Table 40. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) (Million US$) Table 41. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2015-2020) Table 42. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) (Million US$) Table 43. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2015-2020) Table 44. China Key Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue (2019-2020) (Million US$) Table 45. China Key Players Benign Prostatic Hyperplasia (BPH) Treatment Market Share (2019-2020) Table 46. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) (Million US$) Table 47. China Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2015-2020) Table 48. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) (Million US$) Table 49. China Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2015-2020) Table 50. Japan Key Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue (2019-2020) (Million US$) Table 51. Japan Key Players Benign Prostatic Hyperplasia (BPH) Treatment Market Share (2019-2020) Table 52. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) (Million US$) Table 53. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2015-2020) Table 54. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) (Million US$) Table 55. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2015-2020) Table 56. Southeast Asia Key Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue (2019-2020) (Million US$) Table 57. Southeast Asia Key Players Benign Prostatic Hyperplasia (BPH) Treatment Market Share (2019-2020) Table 58. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) (Million US$) Table 59. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2015-2020) Table 60. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) (Million US$) Table 61. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2015-2020) Table 62. India Key Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue (2019-2020) (Million US$) Table 63. India Key Players Benign Prostatic Hyperplasia (BPH) Treatment Market Share (2019-2020) Table 64. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) (Million US$) Table 65. India Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2015-2020) Table 66. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) (Million US$) Table 67. India Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2015-2020) Table 68. Central & South America Key Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue (2019-2020) (Million US$) Table 69. Central & South America Key Players Benign Prostatic Hyperplasia (BPH) Treatment Market Share (2019-2020) Table 70. Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2015-2020) (Million US$) Table 71. Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type (2015-2020) Table 72. Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2015-2020) (Million US$) Table 73. Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2015-2020) Table 74. Pfizer Company Details Table 75. Pfizer Business Overview Table 76. Pfizer Product Table 77. Pfizer Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 78. Pfizer Recent Development Table 79. Sanofi Company Details Table 80. Sanofi Business Overview Table 81. Sanofi Product Table 82. Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 83. Sanofi Recent Development Table 84. GlaxoSmithKline Company Details Table 85. GlaxoSmithKline Business Overview Table 86. GlaxoSmithKline Product Table 87. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 88. GlaxoSmithKline Recent Development Table 89. Boston Scientific Company Details Table 90. Boston Scientific Business Overview Table 91. Boston Scientific Product Table 92. Boston Scientific Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 93. Boston Scientific Recent Development Table 94. Teleflex Company Details Table 95. Teleflex Business Overview Table 96. Teleflex Product Table 97. Teleflex Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 98. Teleflex Recent Development Table 99. Cardinal Health Company Details Table 100. Cardinal Health Business Overview Table 101. Cardinal Health Product Table 102. Cardinal Health Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 103. Cardinal Health Recent Development Table 104. Allergan Company Details Table 105. Allergan Business Overview Table 106. Allergan Product Table 107. Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 108. Allergan Recent Development Table 109. Teva Pharmaceutical Business Overview Table 110. Teva Pharmaceutical Product Table 111. Teva Pharmaceutical Company Details Table 112. Teva Pharmaceutical Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 113. Teva Pharmaceutical Recent Development Table 114. Mylan Company Details Table 115. Mylan Business Overview Table 116. Mylan Product Table 117. Mylan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 118. Mylan Recent Development Table 119. Eli Lilly Company Details Table 120. Eli Lilly Business Overview Table 121. Eli Lilly Product Table 122. Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) (Million US$) Table 123. Eli Lilly Recent Development Table 124. Research Programs/Design for This Report Table 125. Key Data Information from Secondary Sources Table 126. Key Data Information from Primary Sources List of Figures Figure 1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Type: 2020 VS 2026 Figure 2. Drugs Features Figure 3. Devices Features Figure 4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application: 2020 VS 2026 Figure 5. Hospitals Case Studies Figure 6. Clinics Case Studies Figure 7. Others Case Studies Figure 8. Benign Prostatic Hyperplasia (BPH) Treatment Report Years Considered Figure 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth 2015-2026 (US$ Million) Figure 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions: 2020 VS 2026 Figure 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions (2021-2026) Figure 12. Porter's Five Forces Analysis Figure 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Players in 2019 Figure 14. Global Top Benign Prostatic Hyperplasia (BPH) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Treatment as of 2019 Figure 15. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia (BPH) Treatment Revenue in 2019 Figure 16. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 17. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 18. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 20. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 21. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 24. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 25. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 27. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 29. Boston Scientific Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Boston Scientific Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 31. Teleflex Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Teleflex Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 33. Cardinal Health Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Cardinal Health Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 35. Allergan Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. Allergan Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 37. Teva Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Teva Pharmaceutical Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 39. Mylan Total Revenue (US$ Million): 2019 Compared with 2018 Figure 40. Mylan Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 41. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018 Figure 42. Eli Lilly Revenue Growth Rate in Benign Prostatic Hyperplasia (BPH) Treatment Business (2015-2020) Figure 43. Bottom-up and Top-down Approaches for This Report Figure 44. Data Triangulation Figure 45. Key Executives Interviewed

Pfizer Sanofi GlaxoSmithKline Boston Scientific Teleflex Cardinal Health Allergan Teva Pharmaceutical Mylan Eli Lilly